Welcome to our dedicated page for Oncotelic Therapeutics news (Ticker: OTLC), a resource for investors and traders seeking the latest updates and insights on Oncotelic Therapeutics stock.
Oncotelic Therapeutics, Inc. (OTCQB: OTLC) generates a diverse stream of news centered on oncology, rare pediatric cancers, RNA-based therapeutics, AI-driven discovery, and nanomedicine. As a clinical-stage biopharmaceutical company, it regularly reports on scientific publications, joint venture progress, platform launches, and financing developments that shape its pipeline and corporate strategy.
Investors and researchers following OTLC news will encounter updates on key assets such as OT-101, a TGFB2 antisense agent associated with rare pediatric designation for DIPG through joint venture GMP Bio, and Sapu003, an intravenous Deciparticle formulation of everolimus developed by 45% owned JV Sapu Nano. Press releases highlight biomarker frameworks for identifying tumors likely to respond to Sapu003, pharmacokinetic data showing reduced gastrointestinal accumulation compared with oral everolimus, and broader Deciparticle platform data demonstrating formulation of multiple hydrophobic drug classes.
Oncotelic’s news flow also covers its PDAOAI evidence-interrogation platform, including open access for researchers to a TGF-β knowledge corpus of more than 125,000 PubMed abstracts via a dedicated Discord channel. Additional announcements describe peer-reviewed publications on context-dependent biomarkers in liver and pancreatic cancer, sub-15 nm nanoparticles for drug delivery, and survival-associated biological axes such as TGFB2, DNMT3A, and GMPS.
From a corporate and capital markets perspective, OTLC news includes independent valuations of its joint venture GMP Bio pipeline, potential fair-value remeasurements under U.S. GAAP, and registration statements related to equity purchase and note agreements with institutional investors. Regularly reviewing this news page allows readers to track how scientific advances, joint venture activities, AI platforms, and financing structures intersect within Oncotelic’s evolving oncology and rare disease portfolio.
Oncotelic Therapeutics announced that Chief Clinical Officer Dr. Anthony Maida will present at the ASCO 2024 meeting. Key topics include:
1. A meta-analysis (abstract e16318) comparing serious adverse events, overall survival, and progression-free survival in pancreatic adenocarcinoma patients treated with modified FOLFIRINOX versus the standard regimen.
2. A study (abstract e14564) on the prognostic impact of TGFB2 mRNA levels, interferon-gamma receptor activation of IRF5, and CD276/B7-H3 expression in low-grade gliomas.
The presentation aims to provide insights into treatment outcomes and prognostic factors in these cancers.
Oncotelic Therapeutics, Inc (OTCQB:OTLC) will be presenting at the Biopharma Nexus Conference in San Diego 2024. Dr. Andy Hu, Nanomedicine Manager, will discuss Nanomedicines: Past, Present, Future. Dr. Hu is an expert in nanomedicine and biotherapeutics, aiming to enhance human health through innovative technologies.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.